Consider the following medical report that includes the patient's historical health records. Use it to predict the disease that the patient is high likely exposed to. 

 Medical Report: allergies: diphenhydramine attending: chief complaint: dyspnea major surgical or invasive procedure: thoracentesis history of present illness: pt is a 57 year old female with relapsed stage ii c, grade ii papillary serous ovarian cancer on phase i trial (sns 032) presenting with hypoxia, worsening . . pt has known history of lung parenchymal disease from her ovarian cancer as well as bilateral pleural effusions. she was started on phbase 1 trial of sunesis on . has developed progressive sob, , hypoxia with low grade fever (in the ed) over this time. wears oxygen at baseline and has been having increasing requirement from 2l up to 5l oxygen. at baseline, patient is able to walk around her house, but unable to walk short distances without becoming sob. she denies fevers at home, sick contacts, productive , hemoptysis, chest pressure, pleuritic chest pain, or lightheadedness on standing. patient was intiially found in the ed to have o2sats to 85% on ra, up to 94% on nrb, with hr 100-130s. cta negative for pe. patient was found to have increased bilateral pleural effusions from prior. patient admitted to icu for hypoxia. . ros: recently has noted some n/v. also mild constipation. also complaining of significant fatigue. patient denies significant abdominal pain, headache, chills, weight loss, bruising or bleeding. . onc history: dx'd with stage iic ovarian cancer. pathology showed serous papillary adenocarcinoma. she underwent tah, rt spo and cytoreduction which did not remove all lesions. she was then treated with six cycles of carboplatin and taxol until . she relapsed in in the form of a mass in the left hemipelvis. she underwent a second cytoreductive surgery on followed by four cycles of carboplatin and taxol until , which was discontinued because of disease progression. she was then treated with topotecan 1.25 mg/m2 x5 days iv every three weeks for four cycles from until that was discontinued because of a rise in her ca-125. she was treated with doxil 40 mg per meter squared for two cycles on and , which was discontinued because of disease progression based on a ca-125 that was rising. she also developed a rash, mucositis, and hand-foot syndrome. she has been on weekly taxol and arimidex from to and this was discontinued because of disease progression. she received three cycles of gemcitabine but had significant disease progression. she was then on navelbine in but discontinued this in due to disease progression. she was treated with xeloda but progressed on this therapy. she was started on oral etoposide in but discontinued it in gi side effects and fatigue. . currently on started phase 1 trial on with sunesis. past medical history: - ibs - anxiety - metastatic ovarian ca as above. social history: she has been married for over 30 years. she has 2 kids and 1 grandchild. no alcohol or tobacco use. she lives at home with her husband. family history: mother and sister with breast cancer physical exam: t 100.4 bp 120/88 hr 120s rr 93% o2sat on nrb. rr 33. gen: awake, increased wob. coughing throughout interview. heent: perrl, eomi, clear op, anicteric, mucous membranes dry. neck: no lad, jvd. +supraclavicular lymph node 1 cm rubbery. lymph: right supraclavicular ln. left axillary ln. no cervical or inguinal lad. lungs: decreased bs throught left lung. dullness to percussion over left lung, and base of right lung. no wheezing, rales, or rhonchi. heart: tachycardic. abd: soft, nt, nd +bs. purplish subcutaneous 3 cm nodule to left of umbilicus, representing metastatic disease. ext: no edema, 2+ dp/pt. neuro: a&o times 3, no focal deficits pertinent results: . labs/studies: 138 100 16 / 107 agap=13 ------------ 3.8 29 0.6 \ ca: 7.9 mg: 2.0 p: 3.9 alt: 28 ap: tbili: 0.3 ast: 26 urica:2.6 85 6.8 d \ 14.5 / 440 -------- 43.0 n:74.3 band:7.9 l:6.9 m:8.9 e:0 bas:0 atyps: 2.0 . cxr- as best can be compared across modalities, there is a markedly stable radiograph with bilateral pleural effusions, left much greater than right. the left effusion has loculated components with a large intrafissural subcomponent as well. . cta chest: 1. no pulmonary embolism. no aortic dissection. 2. interval worsening of large left loculated pleural effusion and small right pleural effusion. 3. similar appearance of right lower lobe total consolidation due to aspiration. 4. interval slight worsening of thoracic metastatic disease. brief hospital course: this is a 57 yo female with relapsing ovarian cancer with metastatic disease to the lymph nodes, lungs, pleural effusions presents with worsening dyspnea. . 1. pt. with known bilateral pleural effusions secondary to malignant effusions from ovarian cancer. she just started a phase 1 chemotherapy trial with sns03 on and presented to with sob. there was no evidence of pe on cta but the ct did show worsening of the loculated bilateral pleural effusions, which was the most likely etiology of her dyspnea. she also had low grade fevers and was immunosupressed from chemotherapy. therefore, she was started on levofloxacin for possible underlying pneumonia. the patient was oxygen dependent was being treated with standing nebulizer treatments. additionally, we performed a therapeutic thoracentesis under ultrasound guidance. overtime the shortness of breath did not improve, despite these measures. the patient continued to deteriorate. a family meeting was called to discuss further options for intervention and goals of care. after extensive conversation with the attending and the family and patient, the following was decided upon: no further chemotherapy, no further interventions. the patients code status was made dnr/dni and the focus of her care became comfort measures. the patient expired on at 3:20pm with her family at her bedside. 2. ovarian cancer- unfortunately the patient had relapsed disease and failed multiple chemo regimens. on presentation to she was on a phase 1 trial drug, sunesis. the decision was made to stop chemotherapy. medications on admission: - paxil 20 mg daily - centrum silver multivitamin 1 tablet daily (start unknown) - warfarin 1mg daily - lorazepam 1 mg prn - ambien 10mg qpm - albuterol nebulizer prn (approx 3 times a week) - chemotherapy regimen sunesis cycle 1/day 2 - prednisone (recently completed course - ?for breathing) discharge medications: deceased discharge disposition: expired discharge diagnosis: ovarian cancer discharge condition: deceased discharge instructions: deceased followup instructions: deceased md procedure: thoracentesis diagnoses: pneumonia, organism unspecified secondary malignant neoplasm of pleura secondary malignant neoplasm of lung secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes anemia in neoplastic disease personal history of malignant neoplasm of ovary 

Answer: The patient is high likely exposed to